// App-Quantinova.ai

: Phase Ib study of apalutamide (APA) with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Update on safety and efficacy.

Researchers

Presenter

  • Edwin M. Posadas

Principal Investigators

  • Kim N. Chi

  • Ronald De Wit

  • Maja J. De Jonge

  • Gerhardt Attard

  • Terence W. Friedlander

  • Margaret K. Yu

  • Peter Hellemans

  • Caly Chien

  • Charlene Connelly Abrams

  • Martha Gonzalez

  • Geralyn Carol Trudel

  • Vijay Chauhan

  • Juhui James Jiao

  • Fred Saad

Medical Centers

  • Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai, Los Angeles, CA

  • British Columbia Cancer Agency, Vancouver, BC, Canada

  • Erasmus Medical Center Cancer Institute, Rotterdam, Netherlands

  • The Institute of Cancer Research & The Royal Marsden, London, Spain

  • University of California, San Francisco, San Francisco, CA

  • Janssen Research & Development, Los Angeles, CA

  • Janssen Research & Development, Beerse, Belgium

  • Janssen Research and Development, Titusville, NJ

  • Janssen Research and Development, LLC, Spring House, PA

  • Janssen Research & Development, LLC, Raritan, NJ

  • University of Montreal, Montreal, QC, Canada

Locations

  • United States

  • Canada

  • Netherlands

  • United Kingdom

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • CB-7598

  • Prednisone

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT02123758

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved